Inactive

Note: This synopsis follows a Small Business Sources Sought notice that was released on May 07, 2020 under NIH-NCI-SBSS-ETSB-00033. THIS IS A NOTICE OF INTENT, NOT A REQUEST FOR PROPOSAL. A SOLICITATI... Note: This synopsis follows a Small Business Sources Sought notice that was released on May 07, 2020 under NIH-NCI-SBSS-ETSB-00033. THIS IS A NOTICE OF INTENT, NOT A REQUEST FOR PROPOSAL. A SOLICITATION WILL BE ISSUED ON A LATER DATE. Title: Cervical Cancer Screening Follow Up Description: The National Cancer Institute (NCI) has funded previous studies conducted at Kaiser Permanente Northern California to collect biospecimens for biomarker testing and to study risk estimates for cervical cancer screening. The NCI acquired detailed clinical and risk factor history and follow-up data for over 100,000 women enrolled in previous studies with Kaiser Permanente Northern California (KPNC). In addition, the NCI has analyzed similar data for over 1.5 million women screened for cervical cancer at KPNC clinics. Despite Human Papillomavirus (HPV) vaccines, screening will remain central for decades to control cervical cancer. Recently, HPV testing alone or with cytology was introduced in the US as an alternative to cytology screening. However, most HPV infections are harmless and additional tests are required to identify women at highest cancer risk. Purpose and Objectives: The purpose of this requirement is to acquire follow-up, de-identified, clinical data from participants in the KPNC studies. The Contractor shall provide the results of all HPV and cytology-based testing as well as all colposcopy, biopsy and treatment procedures, as well as relevant co-factor data, within the screening program for women at KPNC. The data sets are based on evaluations and analysis made over the course of a year. For each phase there is one data set. The total number of data sets anticipated is five. Specific tasks to be performed by the Contractor include the following: The Contractor shall use existing laboratory and clinical datasets within the KPNC integrated health services delivery system to deliver the following data to NCI: age at visits, STD information (chlamydia, HIV, gonorrhea), hormonal contraception use, smoking status, BMI, and entire history of HPV, Pap results, and all coded cervix histology results (from biopsy, excisional procedures or hysterectomy), previous and future enrollment status. Cervix histology results not previously coded shall be coded prior to delivery of the dataset. Period of Performance The Government anticipates one award will be made for a one (1) year base period and four (4) 12-month options as follows: Base Period: 03/01/2021 – 02/28/2022 Option Period One (1): 03/01/2022 – 02/28/2023 Option Period Two (2): 03/01/2023 – 02/29/2024 Option Period Three (3): 03/01/2024 – 02/28/2025 Option Period Four (4): 03/01/2025 – 02/28/2026 This acquisition will be competed through Sole Source. If a vendor is capable of performing the specified work above, please contact the point of contacted listed below. This notice does not commit the Government to award a contract. No collect calls will be accepted. No facsimile will be accepted. Contracting Office Address: 9609 Medical Center Drive Bethesda, Maryland 20852 Primary Point of Contact: Ogochukwu Nwankwo Contract Specialist Ogochukwu.nwankwo@nih.gov Phone: (240) 276-7504 Secondary Point of Contact: Rukshani Levy Contracting Officer & Team Lead Rukshani.levy@nih.gov Phone: (240) 276-5425